Persons with MS should not stop taking their Disease-Modifying Therapy (DMT). However, some DMTs are more immunosuppressive than others and may increase an individual’s risk of contracting infection. Recommendation:
Persons on certain DMTs, especially alemtuzumab, cladribine, ocrelizumab or rituximab, or fingolimod or siponimod should discuss with their healthcare provider any modifications for these treatments. Also, ask your healthcare provider about the feasibility of postponing visits to the lab or MRI facility for routine monitoring.